Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Pfizer (Italy)
h-index: 77
Total citations: 39,118
Total papers: 740
Homepage:
http://www.pfizer.it/
Recent papers from Pfizer (Italy)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Nature Medicine · 2020
A cost-effectiveness analysis of 21-valent and 20-valent pneumococcal conjugate vaccines in adults aged 65 years in Italy
Annali di igiene medicina preventiva e di comunità · 2026
A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines
Vaccines · 2026
Estimated glomerular filtration rate trajectories by transthyretin stabilisation status in ATTR-ACT
European Heart Journal · 2026
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
European Heart Journal · 2026
Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACT
European Heart Journal · 2026
Phase 3, randomised, placebo‐controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE
British Journal of Haematology · 2026
A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer
Future Oncology · 2026
AI-Enabled Early Intracranial Volumetric Response Predicts Systemic Progression Free Survival in the Phase III CROWN Study
Neuro-Oncology Advances · 2026
Infection prevention and management in patients with multiple myeloma treated with bispecific antibodies: a case-based approach for routine clinical practice
Clinical Lymphoma Myeloma & Leukemia · 2026
Population Pharmacokinetics and Exposure–Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non‐Muscle Invasive Bladder Cancer and Other Solid Tumors
The Journal of Clinical Pharmacology · 2026
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus
Cancers · 2026
Can We Compare Adverse Event’s Attributable Risk Using a Self-Controlled Case Series Design for Vaccine Safety? A Guillain-Barré Syndrome Use Case
Infectious Diseases and Therapy · 2026
Evolution of Hemophilia Management in Italy: Results from a Delphi Consensus Study
Journal of Clinical Medicine · 2026
The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries
Infectious Diseases and Therapy · 2026
2821-LB: Semaglutide Improves Tissue-Specific Insulin Action and Reduces Liver Fat in Type 2 Diabetes with Spinal Cord Injury
Diabetes · 2026
2822-LB: Semaglutide Improves Postprandial Glucose Metabolism after Spinal Cord Injury: A First Mechanistic Study
Diabetes · 2026
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology · 2026
Phylogenetic insights into Dyopsinae (Lepidoptera, Noctuidae): Resolving the systematic position of Thiacidinae
Systematic Entomology · 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
Annals of Oncology · 2026